2F11 Antibody Targeting Alpha-Synuclein Oligomers

The patent applies local quality by designing antibodies with specific complementarity determining regions (CDRs) that are optimized to recognize and bind to the unique 3-dimensional conformational epitopes of toxic oligomeric alpha-synuclein. The CDRs are engineered to have specific amino acid sequences and structural characteristics that provide selective affinity for the pathogenic oligomeric form while excluding non-toxic monomeric or fibrillar forms, thereby achieving local specificity at the molecular binding interface.

The patent employs parameter changes by modifying the structural and conformational parameters of the antibody molecules, particularly the CDR regions, to optimize their binding characteristics. The antibodies are designed with specific affinity constants, binding kinetics, and conformational recognition capabilities that enable them to selectively target the toxic oligomeric form. This involves tuning parameters such as binding strength, epitope recognition geometry, and molecular flexibility to achieve high specificity for the pathogenic species.

The patent applies the intermediary principle by engineering the therapeutic antibodies with dual functionality: they maintain their specific binding capability for toxic oligomeric alpha-synuclein while incorporating molecular features that enable blood-brain barrier penetration. This may involve modifying the antibody's Fc region, adding transcytosis signals, or conjugating with molecules that facilitate transport across the BBB, thereby acting as an intermediary structure that bridges the gap between specific recognition and tissue access.

The patent implements multi-functionality by designing antibodies that simultaneously perform multiple functions: (1) specific recognition and binding to toxic oligomeric alpha-synuclein through engineered CDRs, (2) penetration of the blood-brain barrier via incorporated transport mechanisms, and (3) potential therapeutic action through neutralization or clearance of the pathogenic species. This multi-functional design allows a single antibody molecule to address multiple barriers and achieve both diagnostic and therapeutic goals.

The patent applies preliminary anti-action by designing antibodies that can preemptively bind to toxic oligomeric alpha-synuclein species before they undergo further pathological transformation into more stable aggregates or fibrils. The antibodies are engineered to recognize early oligomeric intermediates and stabilize them in a non-toxic conformation or facilitate their clearance, thereby preventing the progression of pathological misfolding and aggregation cascades that lead to neurodegeneration.

The patent employs the principle of converting harm into benefit by using the antibody's binding action to transform the harmful toxic oligomeric species into a benign state. Through high-affinity binding, the antibodies neutralize the toxic activity of the oligomers, prevent their further aggregation, and may facilitate their degradation or clearance by cellular machinery. The pathogenic oligomers, which would otherwise cause neuronal damage, are converted into antibody-bound complexes that can be safely processed and removed from the system.